What Is B7-33 Peptide?
B7-33 is a synthetic, single-chain peptide derived from the B-chain of human relaxin-2 (H2 relaxin). It is a modified B-chain analog rather than the native two-chain relaxin molecule. The B7-33 sequence corresponds to residues 7–29 of the H2 relaxin B-chain with a KRSL extension at the C-terminus.
B7-33 is therefore classified as a single-B-chain relaxin analog. The peptide was designed from the H2 relaxin B-chain and retains the structural features associated with interaction with relaxin family peptide receptor 1 (RXFP1). Unlike native H2 relaxin, B7-33 is a linear, single-chain peptide rather than a disulfide-linked A–B chain structure.
Research Overview Table
Chemical and Molecular Characteristics
B7-33 is a single-chain derivative of the H2 relaxin B-chain. The reported design removes six residues from the N-terminus of the native B-chain and adds four C-terminal residues, KRSL. Cysteine residues at positions 11 and 23 are replaced by serine residues. The study reports that these substitutions prevent peptide dimerization and aggregation and produce a water-soluble B-chain derivative.
The resulting structure differs from native H2 relaxin, which contains separate A and B chains connected by three disulfide bonds. In solution, two-dimensional NMR analysis found that B7-33 lacks the defined helical features present in the corresponding region of native H2 relaxin and predominantly adopts a random-coil conformation.
Certificates:
Mechanism of Action Under Investigation
B7-33 acts as a functionally selective agonist of RXFP1, a G protein-coupled receptor. Binding studies identified the relaxin B-chain RXXXRXXI sequence as important for RXFP1 recognition, with ArgB13, ArgB17 and IleB20 contributing to receptor interaction.
Substitution of these residues substantially reduced B7-33 binding and RXFP1 activity. B7-33 showed weak activation of cAMP signaling but preferential activation of ERK1/2 phosphorylation (pERK1/2) in cells expressing endogenous RXFP1.
In rat renal myofibroblasts, B7-33 increased pERK1/2 activity and MMP-2, and the MMP-2 response was blocked by an RXFP1 antagonist. An AT2 receptor antagonist also blocked the response, which led the researchers to suggest that RXFP1–AT2 receptor heterodimers may participate in the signaling process. The mechanism was investigated using receptor-binding assays, cAMP measurements, ERK1/2 phosphorylation assays, receptor antagonists, and gelatin zymography. The reason B7-33 produces stronger ERK1/2 signaling in fibroblasts than in recombinant RXFP1 systems remains unresolved.
Scientific Research Context
B7-33 has a predominantly preclinical evidence base that began with peptide design and receptor characterization studies and later expanded into cell-based research and animal studies. The literature now includes multiple peer-reviewed investigations, with the strongest body of evidence coming from in vitro experiments and rodent models. Later publications have continued to evaluate B7-33 as a relaxin-derived research peptide and have explored structural derivatives based on the original B7-33 scaffold. However, the research is still at the preclinical stage. No controlled human research on B7-33 exists.
B7-33 Biology and Biological Pathways
Primary Biological Function
Researchers have investigated B7-33 within the relaxin–RXFP1 biological system. Its biological activity is associated with RXFP1, the cognate receptor for H2 relaxin. Research on B7-33 therefore focuses on its role as a relaxin-derived peptide within this receptor system.
Relevant Metabolic or Signaling Pathways
The main pathways associated with B7-33 are cAMP and ERK1/2 signaling downstream of RXFP1. Experimental studies show that B7-33 can activate cAMP signaling, although with much lower potency than H2 relaxin, while producing stronger ERK1/2 phosphorylation in cells that endogenously express RXFP1. This pattern is described as biased or functionally selective signaling, with greater ERK1/2 activity relative to cAMP activation.
Tissue-Specific Biology
B7-33 research has examined cardiac, pulmonary, renal, and vascular tissues. Vascular studies include the mesenteric artery, small renal artery, and abdominal aorta, while cardiac and pulmonary studies have examined tissue-specific responses to B7-33 in experimental models.
Experimental Biomarkers
The main experimental biomarkers reported for B7-33 are cAMP, phosphorylated ERK1/2 (pERK1/2), and matrix metalloproteinase-2 (MMP-2). cAMP and pERK1/2 were measured as signaling readouts. While MMP-2 was measured as a downstream molecular response in fibroblast studies. These markers are directly reported in published B7-33 experiments.
Laboratory Investigation Methods
Published B7-33 studies have used receptor-binding assays, cAMP assays, ERK1/2 phosphorylation assays, gelatin zymography, Western blotting, and ex vivo vascular wire myography. These methods have been used to examine receptor interaction, intracellular signaling, MMP-2 activity, protein phosphorylation, and vascular function in experimental B7-33 research.
Experimental Models Used in Published Research
Published B7-33 studies have used cell culture, ex vivo tissue, and animal models. The models range from controlled receptor-expression systems to native cells, isolated vascular tissues, and whole-animal disease models. Their main limitations are differences in receptor expression, loss of normal tissue or systemic context, species-specific biology, and the simplified conditions of experimentally induced disease models.
Cell Culture Models
Published B7-33 studies have used RXFP1-expressing HEK-293T cells, THP-1 cells, human cardiac fibroblasts, rat renal myofibroblasts, primary mouse cardiomyocytes, and primary mouse cardiac fibroblasts. The main limitations are artificial receptor expression in engineered cells, simplified conditions in isolated cultures, and species or cell-type differences between animal-derived cells and human biology.
Ex Vivo Vascular Models
Researchers have used rat mesenteric arteries, small renal arteries, abdominal aortas, and mouse mesenteric arteries as ex vivo vascular models. Their main limitation is the loss of the systemic physiological environment after isolation, including circulating factors, neural regulation, and normal blood-flow conditions.
Rodent Models
In vivo B7-33 studies have used mouse myocardial ischemia-reperfusion, rat myocardial infarction, and mouse isoprenaline-induced cardiomyopathy models, along with experimental pulmonary disease models. These models retain whole-organism physiology but are limited by species differences and the controlled nature of experimentally induced disease.
B7-33 Published Scientific Evidence
The published evidence on B7-33 is still predominantly preclinical. Studies have examined B7-33 in RXFP1 receptor biology, vascular function, cardiac injury and remodeling, and fibrosis. More recent work has also examined B7-33 in biomaterial-based delivery systems. Findings from H2 relaxin or modified B7-33 derivatives are treated separately and are not considered direct evidence for unmodified B7-33.
RXFP1 Receptor Characterization
Researchers investigated B7-33 binding to RXFP1, receptor selectivity, and the structural features involved in receptor recognition. The study examined B7-33 across human, rat, and mouse RXFP1 systems and compared its activity with the related RXFP2 receptor. Structure activity experiments also investigated the roles of the B-chain residues ArgB13, ArgB17, and IleB20 in RXFP1 interaction.
Vascular Biology
B7-33 was studied for its vascular effects, including endothelium-dependent relaxation and endothelial dysfunction. The study compared B7-33 with H2 relaxin in rat mesenteric arteries, small renal arteries, and the abdominal aorta, and in an ex vivo mouse mesenteric artery model exposed to placental trophoblast-conditioned media.
Cardiac Injury and Remodeling
Cardiac research has examined B7-33 in myocardial ischemia-reperfusion injury, myocardial infarction, and isoprenaline-induced cardiomyopathy. Investigated areas include infarct size, cardiac function, adverse ventricular remodeling, myocardial fibrosis, cardiomyocyte hypertrophy, inflammation, vascular density, vascular function and endoplasmic-reticulum stress.
Pulmonary and Renal Fibrosis
Pulmonary research has examined B7-33 in airway remodeling, lung fibrosis, collagen deposition, and airway hyperresponsiveness. The published work also compared B7-33 with H2 relaxin in the context of chronic allergic airway disease.
Central Nervous System Biology
Central nervous system research has examined RXFP1 signaling in pain processing, including the distribution of RXFP1 and relaxin-related neurons in brain regions involved in nociception. The study also investigated B7-33 in relation to mechanical and thermal sensitivity under inflammatory pain conditions and compared its effects with H2 relaxin and an RXFP1 antagonist.
Biomaterial Applications
Research has examined B7-33 as a sustained-release peptide incorporated into PLGA coatings for implantable materials. The study investigated B7-33 release from the coating. Whether the released peptide retained RXFP1 activity and the resulting fibrotic encapsulation around the coated implants.
Limitations of Current Research
Evidence Is Predominantly Preclinical
The B7-33 evidence base remains centered on cellular, ex vivo, and animal research. Published studies cover receptor biology, vascular systems, cardiac injury, fibrosis, and delivery approaches. The literature has expanded over time, but the available evidence is still primarily experimental rather than clinical.
Human Clinical Evidence
There are no established controlled human clinical studies of B7-33 itself in the peer-reviewed literature reviewed. The available research remains preclinical, so human pharmacokinetic data and controlled clinical data on B7-33 are not yet established.
Species Differences
B7-33 showed different activity across human, rat, and mouse RXFP1 systems. The study reported differences in cAMP responses between the receptor systems, indicating that B7-33 activity was not identical across species. This variation is an important limitation when comparing results obtained from different species.
Study Design Limitations
Differences in treatment timing, dosing, follow-up periods and experimental protocols make the B7-33 studies difficult to compare directly. For example, the vascular study examined an acute response after treatment, while cardiac studies used treatment periods ranging from several days to longer follow-up. These design differences affect how consistently the findings can be interpreted across studies.
Independent Replication
The direct B7-33 literature is still relatively small, and several research areas are represented by only a limited number of studies. The original B7-33 research also established much of the peptide's foundational characterization. More independent studies using separate laboratories and experimental systems would help determine how consistently the published observations can be reproduced.
Long-Term Evidence
Long-term data on unmodified B7-33 peptide are still limited. A 2025 study followed mice for four weeks using a SPION-conjugated B7-33 formulation, not B7-33 alone. Longer follow-up studies of unmodified B7-33 are still lacking, particularly in humans.
Analytical Documentation
HPLC can assess peptide purity and chromatographic impurities, while LC-MS can provide molecular-mass information to support identity testing. NMR spectroscopy is also relevant to B7-33, as published research has used NMR to examine its solution structure. A Certificate of Analysis (COA) can provide batch-specific analytical information, including reported identity and purity results.
Analytical documentation is important in laboratory research because the material being studied should be characterized and distinguished from impurities or unrelated compounds. These methods provide information about the chemical identity and quality of the material being analyzed. They do not establish how the material will behave in a biological system.
Analytical documentation verifies product identity and quality, not biological performance.
Storage and Laboratory Handling
Store B7-33 according to the specific storage conditions provided for the product and formulation. Keep the material properly sealed and protect it from conditions that could affect its quality. Do not assume that one storage condition applies to every B7-33 formulation.
Qualified laboratory personnel should handle B7-33 using clean equipment and procedures that help prevent contamination. Published research has shown that unmodified B7-33 has limited stability in serum in vitro, which supports careful handling of the material. B7-33 is intended for laboratory research use only.
Why choose us?
Direct SARMs is an established supplier of research peptides. We are committed to product quality, reliable service, and helpful customer support.
Our European-made products undergo rigorous purity testing, with clear product information provided for each research material. We also aim to provide dependable shipping and a smooth ordering experience.
Our support team is available to assist with orders, shipping, payments, and general questions. At Direct SARMs, we aim to make the research supply process simple, clear, and reliable.